Viridian Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $72 | $72 | $72 | $72 |
Gross Profit | 72 | -273 | -278 | -263 |
EBITDA | -64,254 | -55,897 | -65,794 | -51,224 |
EBIT | -64,396 | -56,242 | -66,144 | -51,559 |
Net Income | -64,992 | -48,542 | -66,860 | -47,660 |
Net Change In Cash | 72 | 72 | 72 | 72 |
Free Cash Flow | -46,162 | -45,223 | -38,048 | -39,387 |
Cash | 107,667 | 91,641 | 102,827 | 111,597 |
Basic Shares | 63,854 | 61,099 | 49,681 | 43,654 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $314 | $1,772 | $2,963 | $1,050 |
Gross Profit | -1,008 | 1,017 | 2,343 | -27,254 |
EBITDA | -235,365 | -129,388 | -79,290 | -40,346 |
EBIT | -236,687 | -130,143 | -79,910 | -40,885 |
Net Income | -237,734 | -125,444 | -79,416 | -110,984 |
Net Change In Cash | 314 | 1,772 | 2,963 | 1,050 |
Cost of Revenue | 113,280 | -3,598 | 21,051 | |
Free Cash Flow | -185,068 | -94,635 | -54,919 | -29,821 |
Cash | 102,827 | 155,579 | 42,299 | 45,897 |
Basic Shares | 44,755 | 32,087 | 11,918 | 3,557 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$1.02 |
2024-03-31 | -$0.79 |
2023-12-31 | -$1.35 |
2023-09-30 | -$1.09 |
